UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 717, 2009

Altus Pharmaceuticals Inc.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	0-51711	04-3573277
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

610 Lincoln Street, Waltham, Massachusetts		02451
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		781-373-6000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 38.01 ~~Notice~~Other ~~of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing~~Events.

On August 717, 2009, Altus Pharmaceuticals Inc. (~~the~~"Altus" or "~~Company~~we") ~~received~~entered ainto ~~staff~~an ~~deficiency~~option ~~letter~~agreement ~~from~~(the ~~The~~"Option ~~NASDAQ~~Agreement") ~~Stock~~with ~~Market~~Vertex Pharmaceuticals Incorporated ("~~NASDAQ~~Vertex") ~~notifying the Company that~~, ~~based~~granting onAltus ~~the~~or ~~Company’s~~any ~~stockholders’~~of ~~equity~~its assuccessors ~~reported in~~ the ~~Company’s~~right ~~Quarterly~~to ~~Report~~purchase onall ~~Form~~of ~~10-Q for~~ the ~~period ended June 30~~right, ~~2009,~~title ~~the~~and ~~Company~~interest isof ~~not~~Vertex in ~~compliance~~and ~~with~~to ~~the~~Vertex's ~~minimum~~holdings ~~stockholders’ equity requirement~~ of ~~$10~~Altus' ~~million~~redeemable ~~for~~preferred ~~continued~~stock ~~listing~~at ona ~~The~~price ~~NASDAQ~~of ~~Global Market as set forth in NASDAQ Listing Rule 5450(b)(~~$1~~)(A)~~.5 Asmillion ofbefore ~~June~~December 3020, 2009~~, the Company’s stockholders’ equity was approximately $5~~.~~8 million. This notification has no immediate effect on the Company’s listing on The NASDAQ Global Market or on the trading of the Company’s common stock.~~ As ~~provided~~a incondition ~~the~~to ~~NASDAQ’s~~exercising ~~rules~~its option, ~~the~~Altus ~~Company~~must ~~has~~enter ~~until~~into ~~August~~an ~~24,~~agreement ~~2009 to provide NASDAQ~~ with a ~~plan~~third toparty ~~regain~~under ~~compliance~~which ~~with~~that ~~The~~third ~~NASDAQ~~party ~~Global~~covenants ~~Market~~to ~~continued~~indemnify ~~listing~~Vertex ~~requirements.~~for ~~If NASDAQ~~any ~~accepts~~portion of the ~~Company’s~~purchase ~~plan,~~price ofthat ~~which~~Vertex ~~there~~might ~~can~~ be norequired ~~assurance,~~to ~~NASDAQ~~divest ~~may~~in ~~grant~~ the ~~Company~~case upof toa ~~105~~bankruptcy ~~days~~filing ~~from~~by ~~August 7, 2009 to achieve and sustain compliance~~Altus. In Ifconnection ~~NASDAQ~~with ~~determines~~our ~~that~~1999 ~~the~~reorganization, ~~Company’s plan is not sufficient to achieve and sustain compliance~~450,000 itshares ~~will~~of ~~provide~~redeemable ~~written~~preferred ~~notice that the Company’s common~~ stock ~~would~~were beissued ~~subject~~ to ~~delisting~~Vertex ~~from~~with ~~The~~a ~~NASDAQ~~value ~~Global~~of ~~Market~~$3.1 Atmillion. ~~such~~Vertex ~~time,~~has ~~the~~no ~~Company~~stockholder ~~may~~voting ~~request~~rights aand ~~hearing~~is ~~before~~entitled ato ~~NASDAQ~~receive ~~Listing~~dividends ~~Qualifications~~at ~~Panel. In such~~ an ~~event,~~annual ~~the~~rate ~~Company’s~~of ~~common~~$0.50 ~~stock~~per ~~would~~share. ~~remain~~Dividends ~~listed~~are oncumulative ~~The~~whether ~~NASDAQ~~or ~~Global~~not ~~Market~~declared ~~pending a final determination~~ by the ~~panel. The~~Board ~~Company~~of ~~may~~Directors ~~also~~and ~~apply~~have tobeen ~~list~~accrued ~~its~~in ~~common stock on~~ the ~~NASDAQ~~amount ~~Capital~~of ~~Market~~approximately $2.3 ~~The~~million ~~NASDAQ~~at ~~Capital~~June ~~Market~~30, is2009. aUnless ~~continuous~~Altus ~~trading~~exercises ~~market~~the ~~that~~above ~~operates~~mentioned inoption, the ~~same~~redeemable ~~manner~~preferred asstock ~~The~~is ~~NASDAQ~~redeemable ~~Global~~for ~~Market.~~cash ~~All companies whose securities are listed~~ on ~~The~~or ~~NASDAQ~~after ~~Capital~~December ~~Market~~31, ~~must~~2010 ~~meet~~at ~~certain~~the ~~financial~~option ~~requirements and adhere to NASDAQ’s corporate governance standards. The Company believes that it currently meets all~~ of ~~the~~Vertex, ~~requirements~~or ~~for~~at ~~continued~~our ~~listing~~option onat ~~The~~any ~~NASDAQ Capital Market~~time, ~~other~~at ~~than~~a ~~the minimum bid~~ price of ~~at least~~ $110.00~~.The~~ ~~Company~~per isshare ~~considering~~plus ~~its~~accrued ~~options~~and ~~regarding~~unpaid ~~the~~dividends. ~~NASDAQ~~Upon ~~notice~~liquidation, ~~including~~Vertex ~~potentially~~is ~~submitting~~entitled ~~a plan~~ to ~~NASDAQ on or before August 24~~receive, ~~2009~~prior to ~~maintain~~any ~~its~~payment ~~listing~~with onrespect ~~The NASDAQ Global Market or applying~~ to ~~transfer~~ the ~~listing of its~~ common stock, to$10.00 ~~The~~per ~~NASDAQ~~share ~~Capital~~plus ~~Market.A~~accrued ~~copy~~but ofunpaid ~~the~~dividends. In ~~Company’s~~addition, ~~press~~on ~~release dated~~ August 1114, 2009, ~~reporting~~Jill ~~receipt~~Porter ofinformed the ~~deficiency~~Altus ~~letter~~that she is ~~attached~~resigning ~~hereto~~ as ~~Exhibit~~Vice ~~99.1~~President, ~~and~~Process isDevelopment ~~incorporated~~& ~~herein~~Engineering byof ~~reference~~Altus Pharmaceuticals Inc., effective August 21, 2009.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Altus Pharmaceuticals Inc.
August 11, 2009	By:	Georges Gemayel
August 17, 2009	By:	Georges Gemayel
		Name: Georges Gemayel
		Title: President and Chief Executive Officer

Top of the Form

Exhibit Index

Exhibit No.		Description
99.1		Press Release issued by the Company on August 11, 2009

Filing Compare · Altus Pharmaceuticals Inc.